These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11333344)

  • 1. Anti-interleukin-1 therapy in rheumatic diseases.
    Dayer JM; Feige U; Edwards CK; Burger D
    Curr Opin Rheumatol; 2001 May; 13(3):170-6. PubMed ID: 11333344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations of the Deutschen Gesellschaft für Rheumatologie on therapy of rheumatoid arthritis with the interleukin-1-receptor-antagonist Akakinra (KINERET)].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):698-700. PubMed ID: 12491134
    [No Abstract]   [Full Text] [Related]  

  • 3. IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis.
    Gabay C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):113-27. PubMed ID: 11060665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of DMARDs on IL-1Ra levels in rheumatoid arthritis: is there any evidence?
    Cutolo M
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S26-31. PubMed ID: 14989426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy].
    Fiocco U; Vezzù M; Cozzi L; Todesco S
    Reumatismo; 2004; 56(1 Suppl 1):62-73. PubMed ID: 15201942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [IL-1Ra: its role in rheumatoid arthritis].
    Cutolo M
    Reumatismo; 2004; 56(1 Suppl 1):41-5. PubMed ID: 15201939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is IL-1 a good therapeutic target in the treatment of arthritis?
    Burger D; Dayer JM; Palmer G; Gabay C
    Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of rheumatoid arthritis with IL-1 inhibitors.
    Gabay C; Arend WP
    Springer Semin Immunopathol; 1998; 20(1-2):229-46. PubMed ID: 9836379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage.
    Abramson SB; Amin A
    Rheumatology (Oxford); 2002 Sep; 41(9):972-80. PubMed ID: 12209029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
    Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
    Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Bresnihan B
    BioDrugs; 2001; 15(2):87-97. PubMed ID: 11437678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.
    Schiff MH
    Drugs; 2004; 64(22):2493-501. PubMed ID: 15516150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM
    Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The mode of action of cytokine inhibitors.
    Arend WP
    J Rheumatol Suppl; 2002 Sep; 65():16-21. PubMed ID: 12236617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.
    Bendele A; Sennello G; McAbee T; Frazier J; Chlipala E; Rich B
    J Rheumatol; 1999 Jun; 26(6):1225-9. PubMed ID: 10381034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.
    Bresnihan B; Alvaro-Gracia JM; Cobby M; Doherty M; Domljan Z; Emery P; Nuki G; Pavelka K; Rau R; Rozman B; Watt I; Williams B; Aitchison R; McCabe D; Musikic P
    Arthritis Rheum; 1998 Dec; 41(12):2196-204. PubMed ID: 9870876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
    Rubbert-Roth A; Perniok A
    Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.